Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
PubWeight™: 0.75‹?›
Published in Retrovirology on May 09, 2016
Authors
Erwann P Loret1, Albert Darque2,3, Elisabeth Jouve4, Elvenn A Loret2, Corinne Nicolino-Brunet2, Sophie Morange5, Elisabeth Castanier5, Josiane Casanova5, Christine Caloustian5, Charléric Bornet3, Julie Coussirou3, Jihen Boussetta3, Vincent Couallier6, Olivier Blin4, Bertrand Dussol5, Isabelle Ravaux2
Author Affiliations
1: ETRAV Laboratory, Faculty of Pharmacy, Centre National de la Recherche Scientifique (CNRS), Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France. erwann.loret@univ-amu.fr.
2: ETRAV Laboratory, Faculty of Pharmacy, Centre National de la Recherche Scientifique (CNRS), Aix Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, France.
3: Pharmacie Usage Interne, AP-HM, UHC «la Conception», 147 Bd Baille, 13385, Marseille, France.
4: Centre de Pharmacologie Clinique et Evaluations Thérapeutiques (AP-HM), UHC «la Timone», 28 Boulevard Jean Moulin, 13385, Marseille, France.
5: Centre d'Investigation Clinique, Assistance Publique -Hôpitaux de Marseille (AP-HM), University Hospital Center (UHC) «la Conception», 147 Bd Baille, 13385, Marseille, France.
6: Unité Mixte de Recherche CNRS 5251, Institut de Mathématique de Bordeaux, CNRS, Bordeaux 2 University, 33000, Bordeaux, France.
Articles by these authors ⇆